Brief: Burning Rock Receives FDA Breakthrough Device Designation For OverC Multi-Cancer Detection Blood Test
03/01/2023 14:27
Jan 3 (Reuters) - Burning Rock Biotech Ltd BNR.O :
* BURNING ROCK RECEIVED FDA BREAKTHROUGH DEVICE DESIGNATION
FOR
ITS OVERC™ MULTI-CANCER DETECTION BLOOD TEST
Source text for Eikon: ID:nPn3kmjR2a
Further company coverage: BNR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Burning Rock Biotech
See all newsBurning Rock Biotech's Q2 revenue falls, net loss widens on central laboratory weakness
China's Burning Rock Biotech Q1 revenue falls on lower test volumes
China's Burning Rock Biotech Q4 net loss narrows as costs fall
Cancer diagnostics firm Burning Rock Biotech's Q3 revenue rises on pharma R&D growth
Brief: Burning Rock's Oncoguide™ Oncoscreen™ Plus CDX System Now Approved In Japan As A Companion Diagnostic For Capivasertib In Breast Cancer